References
- Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths – United States, 2010–2015. Morb Mortal Wkly Rep 2016;65:1445-52
- Boyer EW. Management of opioid analgesic overdose. N Engl J Med 2012;367:146-55
- Compton WM, Volkow ND, Throckmorton DC, Lurie P. Expanded access to opioid overdose intervention: research, practice, and policy needs. Ann Intern Med 2013;158:65-6
- Narcan® (naloxone hydrochloride) nasal spray [package insert]. Radnor, PA, USA: Adapt Pharma Inc., 2017
- Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. Morb Mortal Wkly Rep 2015;64:631-5
- Lim JK, Bratberg JP, Davis CS, et al. Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med 2016;10:300-8
- Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm 2014;71:2129-35
- Strang J, McDonald R, Alqurshi A, et al. Naloxone without the needle – systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. Drug Alcohol Depend 2016;163:16-23
- Edwards ET, Edwards ES, Davis E, et al. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther 2015;4:89-105
- Peterson AB, Gladden RM, Delcher C, et al. Increases in fentanyl-related overdose deaths – Florida and Ohio, 2013–2015. Morb Mortal Wkly Rep 2016;65:844-9
- Massachusetts Department of Public Health. Data brief: opioid-related overdose deaths among Massachusetts residents. November 2016. Available at: http://www.mass.gov/eohhs/docs/dph/stop-addiction/current-statistics/data-brief-overdose-deaths-nov-2016-ma-residents.pdf [Last accessed 9 May 2017]
- Rhode Island Department of Health. Drug overdose deaths. 19 April 2017. Available at: http://www.health.ri.gov/data/drugoverdoses/ [Last accessed 9 May 2017]
- Krieter P, Chiang N, Gyaw S, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol 2016;56:1243-53
- Amphastar Pharmaceuticals Inc. Naloxone meeting. Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 5 October 2016. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM524334.pdf [Last accessed 9 May 2017]
- Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf 2015;14:1137-46
- Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010;112:226-38
- Kelly AM, Kerr D, Dietze P, et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust 2005;182:24-7